BeiGene
BGNE
#855
Rank
NZ$40.18 B
Marketcap
$351.19
Share price
0.59%
Change (1 day)
20.34%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$27.43

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$28.23. In 2022 the company made an earnings per share (EPS) of -$32.87 a decrease over its 2021 EPS that were of -$25.81.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$27.43-16.54%
2022-$32.8727.35%
2021-$25.81-19.96%
2020-$32.2420.81%
2019-$26.6931.52%
2018-$20.29417.57%
2017-$3.92-37.16%
2016-$6.24158.95%
2015-$2.41

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.70-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.46-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA